mezigdomide
Selected indexed studies
- Mezigdomide and Multiple Myeloma. (N Engl J Med, 2023) [PMID:37646699]
- Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. (Clin Lymphoma Myeloma Leuk, 2024) [PMID:39003099]
- Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. (N Engl J Med, 2023) [PMID:37646702]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. (2024) pubmed
- Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. (2024) pubmed
- Mezigdomide and Multiple Myeloma. (2023) pubmed
- Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. (2023) pubmed
- Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. (2024) pubmed
- Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma. (2024) pubmed
- Mezigdomide Data Show CELMoD Potential. (2023) pubmed
- Mezigdomide for multiple myeloma: a focus on phase 2 trial data. (2025) pubmed
- The Role of CELMoD Agents in Multiple Myeloma. (2025) pubmed
- Novel Treatment Options for Multiple Myeloma. (2025) pubmed